摘要：2026 年 3 月 2 日，国家药监局药审中心（CDE）公示显示，北京科兴生物制品有限公司的三价流感病毒裂解疫苗（MDCK 细胞）临床试验申请获受理，受理号 CXSL2600289。这一动作使国内 MDCK 细胞基质流感疫苗的临床竞速阵营再添劲旅，而恰逢 WHO 宣布 2026-2027 年北半球流感疫苗回归三价配方，技术路线与市场风向的双重契合，让这场研发竞赛更具行业风向标意义。目前，欧林生物、康泰生物联合兰州百灵已率先布局该赛道，国内细胞基质流感疫苗的市场空白正迎来破局关键期。 科兴正式入局 临床竞速形成三足鼎立 3 月 2 日的 CDE 受理信息公示页面，一行新的登记记录格外醒目。北京科兴提交的三价流感病毒裂解疫苗（MDCK 细胞），以预防用生物制品新药 2.2 类的注册分类，正式进入临床审评环节。 作为国内疫苗领域的头部企业，科兴在流感疫苗领域早有布局，其传统鸡胚工艺的三价流感疫苗已在多地参与免费接种项目。此次转战 MDCK 细胞基质，被业内视为对技术升级的必然布局。鸡胚工艺存在生产周期受禽流感疫情影响、毒株适配性有限等短板，而 MDCK 细胞的易培养、增殖快特性，能实

医药板块避险属性正在消亡？ 美以和伊朗发生冲突，医药板块也一起“带头”交“军费”。 今天医药板块跌幅超过3%的题材板块超过8个（今日科创板跌幅1.56%），港股创新药则更加惨烈，两个创新药ETF（159992和515120）分别收跌2.43%和2.6%。 从全球来看，无论是2008年金融危机、2020年新冠疫情早期等危机事件，医疗保健板块较大盘指数相对抗跌（如金融危机，标普500跌幅37%，而医疗保健板块跌幅22%，跑赢大盘15个点），是传统的防御型板块。 不过在地缘政治事件爆发的背景下，其波动率高于国债、黄金，并且在当下国内医药行业更强调出海寻求更高利润基数的大环境下，市场或许会担忧地缘冲突导致的供应链影响。 在经历一波又一波的洗礼之后，这种防御属性有可能正在被削弱。为什么这么说，因为医药行业指数由各个不同的子行业构成，在大量子行业避险属性被削弱后，分化后走势更弱的公司会深度影响板块。 避险资产的核心特征包括需求刚性、现金流稳定性、低波动性、供应链安全和政策免疫性，医药需求的刚性和非周期性毋庸置疑，现金流稳定性普遍较强但开始分化（专利药强，部分仿制药、疫苗、器械开始模型重塑），波动性

Peer-reviewed randomized controlled study by People Science and Mimio Health, published in Nature Scientific Reports LOS ANGELES, March 2, 2026 /PRNewswire/ -- People Science today announced the publication of a randomized, double-blind, placebo-controlled clinical trial conducted with Mimio Health in Nature Scientific Reports, marking an important step forward in the scientific exploration of nutrient-sensing metabolic biology. Continue Reading Scientific Reports, Mimio publication Fasting Mim

The study found that taking Mimio ™ significantly improved key markers of cardiometabolic health, appetite regulation, digestive comfort, and cellular stress compared to placebo. SAN FRANCISCO, March 2, 2026 /PRNewswire/ -- Mimio Health, an award-winning nutraceutical company developing biomimetic products designed from human biology to optimize cellular function, boost performance, and support longevity, today announced the publication of a randomized, double-blind placebo-controlled clinical s

BFC Group简介 BFC Group是一家立足于中国的精品投行，专注于医疗健康领域的并购、专利许可、融资。我们的业务板块涉及中国、美国和欧洲，曾与国内外众多领先的医疗健康公司有过合作并保持着良好的关系。随着在美国和中国一线运营经验的不断积累，我们对客户在本土之外建立公司或扩展业务所面临的挑战有着深刻的理解。 立于塔顶，高瞻之见。 使命愿景 紧跟医疗健康领域趋势，通过合作推动科学突破与创新。 依客户需求制定战略拓展计划，并在目标市场全方位落实与执行。 成为专注医疗健康行业最优秀的投资银行。 No.1 香港资本市场 香港股市总体概览 在2月20日的马年开市仪式上，港交所主席唐家成表示2026年以来港交所已完成24只新股上市，集资额达870亿元，排队等待上市的企业逾488家。唐家成强调，在IPO（首次公开发行）数量提升的同时，港交所的审核标准绝不松懈，将持续维护香港市场的高质量声誉。同时披露，近期港股成交额已突破3000亿元，印证了流动性优化措施的显著成效。2026年，港交所将全力推进上市制度优化、收窄买卖价差等工作，进一步提升市场活力。 上周，港股恒生指数累计上涨0.8%。2026年

LYON, France, March 2, 2026 /PRNewswire/ -- Efor, a global leader specializing in quality and compliance for the Life Sciences industry, today announced the acquisition of DynamixE, Inc., a U.S.-based company recognized for its expertise in Commissioning, Qualification & Validation (CQV), process engineering, automation and digitalization for pharmaceutical and biotechnology industries. Founded in 2013, Efor has built a leading international platform dedicated to quality and compliance for Life

None The last few years have marked a turning point for the pharmaceutical logistics industry. While pharmaceutical distribution has ramped up significantly, capacity for temperature-controlled logistics has tightened dramatically. Customs delays have caused many shipments to be held in staging areas without adequate environmental controls, while others have passed through general-purpose cargo terminals because the specialized infrastructure required did not exist. The outcome is a syst

Cullgen had been seeking approval for a merger with Pulmatrix from the China Securities Regulatory Commission and on February 28, 2026, notified Pulmatrix that Cullgen was terminating the Merger Agreement - Pulmatrix advances existing discussions on alternative merger opportunities - FRAMINGHAM, Mass., March 2, 2026 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products

Xtant received $10.7 million in satisfaction of unsecured promissory note issued to Xtant by Companion Spine plus related working capital adjustments BELGRADE, Mont., March 2, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced that it has received $10.7 million from Companion Spine related to Companion Spine's purchase of Xtant's Coflex® assets and Paradi

HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that members of its management team will participate in the following upcoming investor conferences: Leerink Global Healthcare Conference Location: Miami, FL Fireside chat: Tuesday, March 10,